1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Sanofi SA - Strategy and SWOT Report

Sanofi SA - Strategy and SWOT Report

  • November 2015
  • -
  • MarketLine
  • -
  • 34 pages

Introduction

Sanofi SA - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Features:

- Detailed information on Sanofi SA required for business and competitor intelligence needs

- A study of the major internal and external factors affecting Sanofi SA in the form of a SWOT analysis

- An in-depth view of the business model of Sanofi SA including a breakdown and examination of key business segments

- Intelligence on Sanofi SA’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about Sanofi SA, such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Sanofi (or 'the group') is a France-based international pharmaceutical group engaged in research, development, manufacture and marketing of healthcare products. It offers pharmaceuticals, human vaccines and animal and consumer health products. The group operates in about 100 countries. It is headquartered in Paris, France, and employed 113,496 people as on December 31, 2014. The group recorded revenues of E33,770 million (approximately $44,880.3 million) during the financial year ended December 2014 (FY2014), an increase of 2.5% over FY2013. The operating profit of the group was E6,143 million (approximately $8,164 million) in FY2014, an increase of 20.3% over FY2013. The net profit of the group was E4,390 million (approximately $5,834.3 million) in FY2014, an increase of 18.1% over FY2013

Reasons to Purchase:

- Gain understanding of Sanofi SA and the factors that influence its strategies

- Track strategic initiatives of the company and latest corporate news and actions

- Assess Sanofi SA as a prospective partner, vendor or supplier

- Support sales activities by understanding your customers' businesses better

- Stay up to date on Sanofi SA’s business structure, strategy and prospects

Table Of Contents

Sanofi SA - Strategy and SWOT Report
Company Overview
Business Description
History
Key Employees and Biographies
Company View
Locations and Subsidiaries
SWOT Analysis
Revenue Analysis
Key Competitors
Major Products and Services

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016’, provides in depth analysis ...

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.